Relapsing polychondritis: 2026 so far

Shift from case-only treatment signals to cohort relapse comparisons.

In the months covered, the clearest treatment update came from a retrospective hospital cohort (a study that looks back at existing records). It compared relapse rates during time periods when the same biologic-exposed patients were on biologics versus off biologics. Relapses were reported as less frequent during TNF inhibitor exposure and during exposure to an IL-6 receptor inhibitor than during no-biologic periods, but this study design could not prove that the biologics caused the change. In the same dataset, infection-related hospitalizations during biologic periods could not be estimated with confidence because the numbers were imprecise. This gives added real-world context that some biologic treatment periods lined up with fewer flares, while the serious infection risk stayed uncertain in this study.

Research covered in: June 2026

Airway involvement progressed from single cases to cohort subtyping and imaging comparisons.

From February through September, airway involvement kept coming up as a major reason for symptoms and more intensive care, and reports added more detail on how to describe it. Case reports described cough, wheeze, and breathlessness tied to airway cartilage inflammation or airway collapse (tracheobronchomalacia, when the airway walls become floppy and narrow). In one reported case, care escalated from steroids and nighttime non-invasive ventilation (breathing support through a mask) to immune-targeting medicines and airway procedures such as stenting and laser therapy. A cohort study then grouped airway disease into three bronchoscopy patterns (bronchoscopy is a camera test inside the airways). The most extensive pattern lined up with higher ICU care and tracheostomy needs, and bronchoscopy sometimes triggered short-term respiratory crises in severe cases. In the months covered, this reinforced that airway symptoms in RP can reflect structural airway problems and may lead to specialized testing plus a mix of immune treatment and airway-support approaches.

Research covered in: March 2026, April 2026, May 2026, June 2026, August 2026, September 2026

Monitoring advanced with an RP-specific QoL tool and risk-linked clinical clusters.

In July, the focus shifted toward measuring and sorting RP patterns, rather than introducing new therapies. An RP-specific quality-of-life questionnaire (RP-QoL, a survey about how RP affects daily life) was developed and internationally tested. In that dataset, it showed strong internal consistency and lined up with general health surveys and patient-reported impact, but whether it reliably tracks change over time was not yet established. A separate study grouped 135 hospitalized patients into three clinical patterns with different risk of deterioration. In that work, higher inflammation markers and respiratory involvement characterized a higher-worsening group, and hearing/inner ear features helped separate the clusters. These tools and groupings are meant to make symptom burden and risk patterns easier to measure, especially for research and for sicker hospitalized populations.

Research covered in: July 2026

Cardiac patterns emerged from a single-center cohort with subgroup signals.

In August, one retrospective single-center cohort gave a clearer estimate that cardiac involvement occurred in about 3 in 10 people with RP. The types varied, including aortic root dilation (widening near the start of the aorta), rhythm or conduction findings (electrical timing changes in the heartbeat), and myocarditis/pericarditis assessments (inflammation of the heart muscle or the lining around the heart). These were evaluated using ECG/echo (heart rhythm tracing and ultrasound of the heart) and sometimes cardiac MRI (a detailed heart scan). The same report described a possible 'cardiac-dominant' subgroup that was less likely to have eye involvement or costochondritis (inflammation where ribs meet the breastbone) and tended to have lower LDL cholesterol, which needs confirmation in other groups. In the months covered, this strengthened the picture that heart and nearby vessel issues can be part of RP for a substantial minority in some cohorts and can show up in different ways.

Research covered in: August 2026

Diagnostic work moved from single PET-CT cases to CT/PET-CT syntheses and VEXAS look-alikes.

In the months covered, reports repeatedly stressed that RP can be mistaken for other airway diseases or even airway tumors, and that imaging can help show cartilage-focused inflammation when standard tests do not give clear answers. Case reports highlighted PET-CT patterns (a scan that combines metabolic activity with CT images) showing multi-site cartilage inflammation. They also described situations where symptoms had another cause, such as hearing loss attributed to a different condition in one case. Later work compared CT patterns in RP versus ANCA-associated vasculitis (a blood-vessel inflammation condition linked to ANCA antibodies) and summarized PET/CT positivity across small studies, including detection of cartilage involvement without obvious symptoms. Separately, registry and case-based reports reinforced that some RP-like presentations may be part of broader syndromes such as VEXAS (a genetic inflammatory syndrome confirmed by UBA1 mutation testing), with different risk implications in VEXAS-focused data. In the months covered, this supported why evaluation may include advanced imaging and why clinicians may look for alternative or overlapping diagnoses when the overall pattern does not fit typical RP.

Research covered in: February 2026, March 2026, April 2026, June 2026, July 2026, September 2026